Advertisement

Biotherapy

, Volume 3, Issue 2, pp 167–175 | Cite as

Evaluation of TNF as antiviral, antibacterial and antiparasitic agent

  • Graham A. W. Rook
  • Janice Taverne
  • John H. L. Playfair
Article

Key words

bacteria parasites protection TNF virus 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Havell EA. Production of tumor necrosis factor during murine listeriosis. J Immunol 1987; 139: 4225–31.PubMedGoogle Scholar
  2. 2.
    Nakane A, Minagawa T, Kato K. Endogeneous tumour necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection. Infect Immun 1988; 56: 2563–9.PubMedGoogle Scholar
  3. 3.
    Bancroft GJ, Sheehan KC, Schreiber RD, Unanue ER. Tumor necrosis factor is involved in the T cell-independent pathway of macrophage activation in scid mice. J Immunol 1989; 143: 127–30.PubMedGoogle Scholar
  4. 4.
    Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989; 56: 731–40.PubMedGoogle Scholar
  5. 5.
    Neifer S, Kremsner PG, Bienzle U. Application of anti-TNF to plasmodium vinckei-infected mice is followed by an increase of parasitaemia. Acta Trop (Basel) 1989; 46: 273–5.Google Scholar
  6. 6.
    Titus RG, Sherry B, Cerami A. Tumour necrosis factor plays a protective role in experimental murine cutaneous leismaniasis. J exp Med 1989; 170: 2097–104.PubMedGoogle Scholar
  7. 7.
    Taverne J, Tavernier J, Fiers W, Playfair JH. Recombinant tumour necrosis factor inhibits malaria parasitein vivo but notin vitro. Clin Exp Immunol 1987; 67: 1–4.PubMedGoogle Scholar
  8. 8.
    Clark IA, Hunt NH, Butcher GA, Cowden WB. Inhibition of murine malaria (plasmodium chabaudi)in vivo by recombinant interferon-gamma or tumor necrosis factor, and its enhancement by butylated hydroxyanisole. J Immunol 1987; 139: 3493–6.PubMedGoogle Scholar
  9. 9.
    Black CM, Israelski DM, Suzuki Y, Remington JS. Effect of recombinant tumour necrosis factor on acute infection in mice with toxoplasma gondii or Trypanosoma cruzi. Immunology 1989; 68: 570–4.PubMedGoogle Scholar
  10. 10.
    Bermudez LEM, Stevens P, Kolonoski P, Wu M, Young LS. Treatment of experimental disseminated Mycobacterium avium complex infection in mice with recombinant IL-2 and tumor necrosis factor. J Immunol 1989; 143: 2996–3000.PubMedGoogle Scholar
  11. 11.
    Blanchard DK, Djeu JY, Klein TW, Friedman H, Stewart WE. Protective effects of tumor necrosis factor in experimental Legionella pneumophila infections of mice via activation of PMN function. J Leukoc Biol 1988; 43: 429–35.PubMedGoogle Scholar
  12. 12.
    Parant M. Effects of TNF in bacterial infections. Ann Inst Pasteur Immunol 1988; 139: 301–4.PubMedGoogle Scholar
  13. 13.
    Cross AS, Sadoff JC, Kelly N, Bernton E, Gemski P. Pretreatment with recombinant murine tumour necrosis factor alpha/cachectin and murine interleukin 1 alpha protects mice from lethal bacterial infection. J Exp Med 1989; 169: 2021–7.PubMedGoogle Scholar
  14. 14.
    Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330: 662–4.PubMedGoogle Scholar
  15. 15.
    Doherty PC, Allan JE, Clark IA. Tumour necrosis factor inhibits the development of viral meningitis or induces rapid death depending on the severity of inflammation at the time of administration. J Immunol 1989; 142: 3576–80.PubMedGoogle Scholar
  16. 16.
    Kongshavn PA, Ghadirian E. Effect of tumour necrosis factor on growth of Trypanosoma musculiin vivo andin vitro. Adv Exp Biol Med 1988; 239: 257–62.Google Scholar
  17. 17.
    Usami H, Yamamoto A, Yamashita W, Sugawara Y, Hamada S, Yamamoto T, Kato K, Kokeguchi S, Ohokuni H, Kotani S. Antitumour effects of streptococcal lipoteichoic acids on Meth A fibrosarcoma. Br J Cancer 1988; 57: 70–3.PubMedGoogle Scholar
  18. 18.
    Moreno C, Taverne J, Mehlert A, Bate CA, Brealey RJ, Meager A, Rook GAW, Playfair JHL. Lipoarabinomannan from mycobacterium tuberculosis induces the production of tumour necrosis factor from human and murine macrophages. Clin Exp Immunol 1989; 76: 240–5.PubMedGoogle Scholar
  19. 19.
    Jupin C, Anderson S, Damais C, Alouf JE, Parant M. Toxic shock syndrome toxin 1 as an inducer of human tumor necrosis factors and gamma interferon. J Exp Med 1988; 167: 752–61.PubMedGoogle Scholar
  20. 20.
    Yamamoto A, Nagamuta M, Usami H, Sugawara Y, Watanabe N, Niitsu Y, Urushizaki I. Release of tumour necrosis factor (TNF) into mouse peritoneal fluids by OK432, a streptococcal preparation. Immunopharmacology 1986; 11: 79–86.PubMedGoogle Scholar
  21. 21.
    Noso Y, Parant M, Parant F, Chedid L. Production of tumour necrosis factor in nude mice by muramyl peptides associated with bacterial vaccines. Cancer Res 1988; 48: 5766–9.PubMedGoogle Scholar
  22. 22.
    Bate CA, Taverne J, Playfair JH. Soluble malarial antigens are toxic and induce the production of tumour necrosis factorin vivo. Immunology 1989; 66: 600–5.PubMedGoogle Scholar
  23. 23.
    Djeu JY, Blanchard DK, Richards AL, Friedman H. Tumor necrosis factor induction by candida albicans from human natural killer cells and monocytes. J Immunol 1988; 141: 4047–52.PubMedGoogle Scholar
  24. 24.
    Playfair JHL, Taverne J, Bate CAW, De Souza JB. The malaria vaccine: anti-parasite or anti-disease? Immunology Today 1990; 11: 25–7.PubMedGoogle Scholar
  25. 25.
    Roux-Lombard P, Modoux C, Cruchaud A, Dayer JM. Purified blood monocytes from HIV 1-infected patients produce high levels of TNF alpha and IL-1. Clin Immunol Immunopathol 50: 374-84.Google Scholar
  26. 26.
    Molina JM, Scadden DT, Byrn R, Dinarello CA, Groopman JE. Production of tumor necrosis factor alpha and interleukin 1 beta by monocytic cells infected with human immunodeficiency virus. J Clin Invest 1989; 84: 733–7.PubMedGoogle Scholar
  27. 27.
    Merrill JE, Koyanagi Y, Chen IS. Interleukin-1 and tumor necrosis factor alpha can be induced from mononuclear phagocytes by human immunodeficiency virus type 1 binding to the CD4 receptor. J Virol 1989; 63: 4404–8.PubMedGoogle Scholar
  28. 28.
    Klebanoff SJ, Vadas MA, Harlan JM, Sparks LH, Gamble JR, Agosti JM, Waltersdorf AM. Stimulation of neurophils by tumour necrosis factor. J Immunol 1986; 136: 4220–5.PubMedGoogle Scholar
  29. 29.
    Berkow RL, Dodson MR. Biochemical mechanisms in the priming of neutrophils by tumour necrosis factor. J Leukocyte Biol 1988; 44: 345–52.PubMedGoogle Scholar
  30. 30.
    Ferrante A. Tumor necrosis factor alpha potentiates neutrophil antimicrobial and Candida albicans and associated increases in oxygen radical production and lysosomal enzyme release. Infect Immun 1989; 57: 2115–22.PubMedGoogle Scholar
  31. 31.
    Gamble JR, Harlan JM, Klebanoff SJ, Vadas MA. Stimulation of the adherence of neutrophils to the umbilical vein endothelium by human recombinant tumour necrosis factor. Proc Natl Acad Sci USA 1985; 82: 8667–71.PubMedGoogle Scholar
  32. 32.
    Shalaby MR, Aggarwal BB, Rinderknecht E, Svedersky LP, Finkle BS, Palladino MA. Activation of human polymorphonuclear functions by interferon gamma and tumor necrosis factors. J Immunol 1985; 135: 2069–73.PubMedGoogle Scholar
  33. 33.
    Shalaby MR, Palladino MA, Hirabayashi SE, Eesalu TE, Lewis GD, Shepard HM, Aggarwal BB. Receptor binding and activation of polymorphonuclear neutrophils by tumour necrosis factor alpha. J Leukocyte Biol 1987; 41: 196–204.PubMedGoogle Scholar
  34. 34.
    Djeu JY, Blanchard DK, Halkias D, Friedman H. Growth inhibition of candida albicans by human polymorphonuclear neutrophils: activation by interferon gamma and tumor necrosis factor. J Immunol 1986; 137: 2980–4.PubMedGoogle Scholar
  35. 35.
    Damonneville M, Wietzerbin J, Pancre V, Joseph M, Delanoye A, Capron A, Auriault C. Recombinant tumour necrosis factors mediate platelet cytotoxicity to schistosoma mansoni larvae. J Immunol 1988; 140: 3962–5.PubMedGoogle Scholar
  36. 36.
    DeTitto EH, Catterall JR, Remington JS. Activity of recombinant tumour necrosis factor on toxoplasma gondii and trypanosoma cruzi. J Immunol 1986; 137: 1342–5.PubMedGoogle Scholar
  37. 37.
    Wirth JJ, Kierszenbaum F. Recombinant tumour necrosis factor enhances macrophage destruction of trypanosoma cruzi in the presence of bacterial endotoxin. J Immunol 1988; 141: 286–8.PubMedGoogle Scholar
  38. 38.
    Bermudez LE, Young LS. Tumour necrosis factor, alone or in combination with IL-2, but not IFN-gamma, is associated with macrophage killing of mycobacterium avium complex. J Immunol 1988; 140: 3006–13.PubMedGoogle Scholar
  39. 39.
    Rook GAW, Steele J, Ainsworth M, Champion BR. Activation of macrophages to inhibit proliferation of mycobacterium tuberculosis: comparison of the effects of recombinant gamma-interferon on human monocytes and murine peritoneal macrophages. Immunology 1986; 59: 333–8.PubMedGoogle Scholar
  40. 40.
    Voth R, Rossol S, Gallati H, Pracht I, Laubenstein HP, Hess G, Muller WE, Schroder HC, Jochum C, Meyer-zum-Buschenfelde KH.In vivo andin vitro induction of natural killer cells by cloned human tumour necrosis factor. Cancer Immunol Immunother 1988; 27: 128–32.PubMedGoogle Scholar
  41. 41.
    Silberstein DS, David JR. Tumour necrosis factor enhances eosinophil toxicity of schistosoma mansoni larvae. Proc Natl Acad Sci USA 1986; 83: 1055–9.PubMedGoogle Scholar
  42. 42.
    Whitcombe EA, Wesolek JH, Pincus SH. Modulation of human peripheral blood eosinophil function by tumour necrosis factor alpha. Int Arch Allergy Appl Immunol 1989; 89: 250–5.PubMedGoogle Scholar
  43. 43.
    Alam R, Welter JB, Forsythe PA, Lett-Brown MA, Grant JA. Comparative effect of recombinant IL-1, -2, -3, -4, and -6, IFN- gamma, granulocyte-macrophage-colony-stimulating factor, tumor necrosis factor-alpha, and histaminereleasing factors on the secretion of histamine from basophils. J Immunol 1989; 142: 3431–5.PubMedGoogle Scholar
  44. 44.
    Deare M, Bukholm G, Czarniecki CW.In vitro treatment of HEp-2 cells with human tumour necrosis factor alpha and human interferons reduces invasiveness of salmonella typhimurium. J Biol Regul Homeost Agents 1989; 3: 1–7.PubMedGoogle Scholar
  45. 45.
    Shemer-Avni Y, Wallach D, Sarov I. Reversion of the antichlamydial effect of tumour necrosis factor by tryptophan and antibodies to beta interferon. Infect Immun 1989; 57: 3484–90.PubMedGoogle Scholar
  46. 46.
    Mestan J, Digel W, Mittnacht S, Hillen H, Blohm D, Moller A, Jacobsen H, Kirchner H. Antiviral effect of recombinant tumour necrosis factorin vitro. Nature 1986; 323: 816–9.PubMedGoogle Scholar
  47. 47.
    Wong GHW, Goeddel DV. Tumour necrosis factors alpha and beta inhibit virus replication and synergise with interferons. Nature 1986; 323: 819–22.PubMedGoogle Scholar
  48. 48.
    Ruggiero V, Antonelli G, Conciatori G, Gentile M, Van Damme J, Dianzani F. Thein vitro antiviral activity of tumor necrosis factor (TNF) in WISH cells is mediated by IFN-beta induction. Antiviral Res 1989; 11: 77–88.PubMedGoogle Scholar
  49. 49.
    Janssen O, Kabelitz D. Tumour necrosis factor selectively inhibits activation of human B cells by Epstein-Barr virus. J Immunol 1988; 140: 125–30.PubMedGoogle Scholar
  50. 50.
    Koff WC, Farm AV. Human tumour necrosis factor alpha kills herpesvirus-infected, but not normal cells. Lymphokine Res 1986; 5: 215–21.PubMedGoogle Scholar
  51. 51.
    Matsuyama T, Hamamoto Y, Soma G, Mizuno D, Yamamoto N, Kobayashi N. Cytocidal effect of tumor necrosis factor on cells chronically infected with human immunodeficiency virus (HIV): enhancement of HIV replication. J Virol 1989; 63: 2504–9.PubMedGoogle Scholar
  52. 52.
    Kasahara K, Kobayashi K, Shikama Y, Yoneva I, Kaga S, Hashimoto M, Odagiri T, Soejima K, Ide H, Takahashi T. The role of monokines in granuloma formation in mice: the ability of interleukin-1 and tumour necrosis factor alpha to induce lung granulomas. Clin Immunol Immunopathol 1989; 51: 419–25.PubMedGoogle Scholar
  53. 53.
    Sheppard BC, Fraker DL, Norton JA. Prevention and treatment of endotoxin and sepsis lethality with recombinant human tumor necrosis factor. Surgery 1989; 106: 156–61.PubMedGoogle Scholar
  54. 54.
    Brouckaert P, Spriggs DR, Demetri G, Kufe DW, Fiers W. Circulating Interleukin 6 during an infusion of tumour necrosis factor and interferon gamma. J exp Med 1989; 169: 2257–62.PubMedGoogle Scholar
  55. 55.
    Baumann H, Wong GW. Hepatocyte-stimulating factor III shares structural and functional identity with leukemia-inhibitory factor. J Immunol 1989; 143: 1163–7.PubMedGoogle Scholar
  56. 56.
    Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987; 1: 355–7.PubMedGoogle Scholar
  57. 57.
    Millar AB, Foley NM, Singer M, Johnson NMCI, Meager A, Rook GAW. TNF in bronchopulmonary secretions of patients with adult respiratory distress syndrome. Lancet 1989; ii: 712–4.Google Scholar
  58. 58.
    Kern P, Hemmer CJ, Van-Damme J, Gruss HJ, Dietrich M, Elevated tumor necrosis factor alpha and interleukin-6 serum levels as markers for complicated plasmodium facciparum malaria. Am J Med 1989; 87: 139–43.PubMedGoogle Scholar
  59. 59.
    Clark IA, Chaudhri G. Tumour necrosis factor may contribute to the anaemia of malaria by causing dyserythropoiesis and erythrophagocytosis. Br J Haematol 1988; 70: 99–103.PubMedGoogle Scholar
  60. 60.
    Clark IA, Chaudhri G. Tumor necrosis factor in malaria-induced abortion. Am J Trop Med Hyg 1988; 39: 246–9.PubMedGoogle Scholar
  61. 61.
    Grau GE, Fajardo LF, Piguet PF, Allet B, Lambert PH, Vassalli P. Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria. Science 1987; 237: 1210–2.PubMedGoogle Scholar
  62. 62.
    Mintz M, Rapaport R, Oleske JM, Connor EM, Koenigsberger MR, Denny T, Epstein LG. Elevated serum levels of tumor necrosis factor are associated with progressive encephalopathy in children with acquired immunodeficiency syndrome. Am J Dis Child 1989; 143: 771–4.PubMedGoogle Scholar
  63. 63.
    Folks TM, Clouse KA, Justement J, Rabson A, Duh E, Kehrl JH, Fauci AS. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci USA 1989; 86: 2365–8.PubMedGoogle Scholar
  64. 64.
    Okamoto T, Matsuyama T, Mori S, Hamamoto Y, Kobayashi N, Yamamoto N, Josephs SF, Wong-Staal F, Shimotohno K. Augmentation of human immunodeficiency virus type I gene expression by tumor necrosis factor alpha. AIDS Hum Retroviruses 1989; 5: 131–8.Google Scholar
  65. 65.
    Ito M, Baba M, Sato A, Hirabayashi K, Tanabe F, Shigeta S, De-Clercq E. Tumor necrosis factor enhances replication of human immunodeficiency virus (HIV)in vitro. Biochem Biophys Res Commun 1989; 158: 307–12.PubMedGoogle Scholar
  66. 66.
    Duh EJ, Maury WF, Folks TM, Fauci AS, Rabson AB. Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proc Natl Acad Sci USA 1989; 86: 5974–8.PubMedGoogle Scholar
  67. 67.
    Aboulafia D, Miles SA, Saks SR, Mitsuyasu RT. Intravenous recombinant tumor necrosis factor in the treatment of AIDS-related Kaposi's sarcoma. J Acquir Immune Defic Syndr 1989; 2: 54–8.PubMedGoogle Scholar
  68. 68.
    Tracey KJ, Wei H, Manogue KR, Fong Y, Hesse DG, Nguyen HT, Kuo GC, Beutler B, Cotran RS, Cerami A. Cachectin/tumor necrosis factor induces cachexia, anaemia, and inflammation. J Exp Med 1988; 167: 1211–27.PubMedGoogle Scholar
  69. 69.
    Waage A, Espevik T. Interleukin-I potentiates the lethal effect of tumour necrosis factor alpha/cachectin in mice. J Exp Med 1988; 167: 1987–92.PubMedGoogle Scholar
  70. 70.
    Rothstein J, Schreiber H. Synergy between tumour necrosis factor and bacterial products causes haemorrhagic necrosis and lethal shock in normal mice. Proc Natl Acad Sci 1988; 85: 607–11.PubMedGoogle Scholar
  71. 71.
    Rook GAW, Taverne J, Leveton C, Steele J. The role of gamma-interferon, vitamin D3 metabolites and tumour necrosis factor in the pathogenesis of tuberculosis. Immunology 1987; 62: 229–34.PubMedGoogle Scholar
  72. 72.
    Rook GAW. The role of cytokines in the immunopathology of tuberculosis and the regulation of agalactosyl IgG. Lymphokine Research 1989; 8: 323–8.PubMedGoogle Scholar
  73. 73.
    Pober JS. TNF as an activator of vascular endothelium. Ann Inst Pasteur Immunol 1988; 139: 317–23.PubMedGoogle Scholar
  74. 74.
    Aderka D, Levo Y. Does tumor necrosis factor play a role in the pathogenesis of fulminant hepatitis? Med Hypotheses 1988; 27: 193–6.PubMedGoogle Scholar
  75. 75.
    Wallach D, Holtmann H, Engelmann H, Nophar Y. Sensitisation and desensitisation to lethal effects of tumour necrosis factor and IL-1. J Immunol 1988; 140: 2994–9.PubMedGoogle Scholar
  76. 76.
    Kiener PA, Marek F, Rodgers G, Lin PF, Warr G, Desiderio J. Induction of tumour necrosis factor, IFN-gamma, and acute lethality in mice by toxic and non-toxic forms of lipid A. J Immunol 1988; 141: 870–4.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1991

Authors and Affiliations

  • Graham A. W. Rook
    • 1
  • Janice Taverne
    • 2
  • John H. L. Playfair
    • 2
  1. 1.Department of Medical MicrobiologyUniversity College and Middlesex School of MedicineLondonUK
  2. 2.Department of ImmunologyUniversity College and Middlesex School of MedicineLondonUK

Personalised recommendations